Literature DB >> 2169657

Effects of low molecular weight heparin and unfragmented heparin on induction of osteoporosis in rats.

T Mätzsch1, D Bergqvist, U Hedner, B Nilsson, P Ostergaard.   

Abstract

A comparison between the effect of low molecular weight heparin (LMWH) and unfragmented heparin (UH) on induction of osteoporosis was made in 60 rats treated with either UH (2 IU/g bw), LMWH in 2 doses (2 XaI U/g or 0.4 XaI U/g) or placebo (saline) for 34 days. Studied variables were: bone mineral mass in femora; fragility of humera; zinc and calcium levels in serum and bone ash and albumin in plasma. A significant reduction in bone mineral mass was found in all heparin-treated rats. There was no difference between UH and LMWH in this respect. The effect was dose-dependent in LMWH-treated animals. The zinc contents in bone ash were decreased in all heparin-treated rats as compared with controls. No recognizable pattern was seen in alterations of zinc or calcium in serum. The fragility of the humera, tested as breaking strength did not differ between treatment groups and controls. In conclusion, if dosed according to similar factor Xa inhibitory activities, LMWH induces osteoporosis to the same extent as UH and in a dose-dependent manner. The zinc content in bone ash was decreased after heparin treatment, irrespective of type of heparin given.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2169657

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  12 in total

Review 1.  Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  David A Garcia; Trevor P Baglin; Jeffrey I Weitz; Meyer Michel Samama
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Disruption of cell-matrix interactions by heparin enhances mesenchymal progenitor adipocyte differentiation.

Authors:  Weijun Luo; Hailu Shitaye; Michael Friedman; Christina N Bennett; Joshua Miller; Ormond A Macdougald; Kurt D Hankenson
Journal:  Exp Cell Res       Date:  2008-07-12       Impact factor: 3.905

3.  Histopathologic effects of a low molecular weight heparin on bone healing in rats: a promising adjuvant in dacryocystorhinostomy.

Authors:  Mehmet Numan Alp; Ozdamar Fuad Oken; Mustafa Fevzi Sargon; Ahmet Ucaner
Journal:  Int J Ophthalmol       Date:  2016-06-18       Impact factor: 1.779

4.  The influence of low molecular weight heparin on the expression of osteogenic growth factors in human fracture healing.

Authors:  Kambiz Sarahrudi; Georg Kaiser; Anita Thomas; Mark Michel; Harald Wolf; Mehdi Mousavi; Seyedhossein Aharinejad
Journal:  Int Orthop       Date:  2011-10-29       Impact factor: 3.075

5.  Managing elderly people's osteoporosis. Why? Who? How?

Authors:  A Juby
Journal:  Can Fam Physician       Date:  1999-06       Impact factor: 3.275

Review 6.  Effects of Long-Term Low-Molecular-Weight Heparin on Fractures and Bone Density in Non-Pregnant Adults: A Systematic Review With Meta-Analysis.

Authors:  Olga Gajic-Veljanoski; Chai W Phua; Prakesh S Shah; Angela M Cheung
Journal:  J Gen Intern Med       Date:  2016-02-19       Impact factor: 5.128

7.  Effect of medication on biomechanical properties of rabbit bones: heparin induced osteoporosis.

Authors:  N Akkas; Y N Yeni; B Turan; E Delilbasi; U Gunel
Journal:  Clin Rheumatol       Date:  1997-11       Impact factor: 2.980

8.  Selenium combined with vitamin E and vitamin C restores structural alterations of bones in heparin-induced osteoporosis.

Authors:  Belma Turan; Belgin Can; Ertan Delilbasi
Journal:  Clin Rheumatol       Date:  2003-10-31       Impact factor: 2.980

Review 9.  Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins.

Authors:  M Verstraete
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

Review 10.  Tinzaparin. A review of its pharmacology and clinical potential in the prevention and treatment of thromboembolic disorders.

Authors:  H A Friedel; J A Balfour
Journal:  Drugs       Date:  1994-10       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.